Pharma BD Deal Intelligence

Eli Lilly and Company / Avid Radiopharmaceuticals, Inc.

2010 · Acquisition/Merger · $800M · Complete

Announcement Sentiment

Strongly positive

Lilly to acquire Avid Radiopharmaceuticals for $300M upfront + up to $500M regulatory/commercial milestones. Florbetapir later approved as Amyvid (2012).

Did it work? Outcome assessment

Strategic verdict

Partially Achieved

Financial impact

Neutral

Pipeline outcome

Assets Advanced

Assessment window: 15yr post-close.

Key facts

Announced Nov 08, 2010
Closed Dec 23, 2010
Deal value $800M
Deal type Acquisition/Merger
Therapeutic area Alzheimer's disease imaging
Indications Alzheimer's disease imaging
Key assets Florbetapir F18 (Amyvid)
Mechanism Beta-amyloid PET imaging agent

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals